Results 151 to 160 of about 2,864 (172)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging

Drug Development Research, 2019
Feng Sun, Wenhong Zhang
exaly  

Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Clinical Infectious Diseases, 2020
Kwonjune J Seung, Palwasha Khan, Molly F Franke   +2 more
exaly  

Progress of Delamanid in the Treatment of Tuberculosis

2022 International Conference on Biotechnology, Life Science and Medical Engineering (BLSME 2022), 2022
openaire   +1 more source

In reply. QTc prolongation and delamanid: access and safety

The International Journal of Tuberculosis and Lung Disease, 2015
Jennifer, Furin, Elizabeth, Harausz, Peter, Zimetbaum, Helen, Cox   +3 more
openaire   +2 more sources

Clinical Outcomes Among Patients With Drug-resistant Tuberculosis Receiving Bedaquiline- or Delamanid-Containing Regimens

Clinical Infectious Diseases, 2019
Russell R Kempker, Charles A Peloquin, Henry M Blumberg   +2 more
exaly  

Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis

European Journal of Clinical Microbiology and Infectious Diseases, 2019
Zhaojing Zong, Yuanyuan Shang, Hairong Huang   +2 more
exaly  

Bedaquiline/delamanid

Reactions Weekly, 2017
openaire   +1 more source

Delamanid Does Not Inhibit or Induce Cytochrome P450 Enzymes <i>in Vitro</i>

Biological and Pharmaceutical Bulletin, 2014
Yoshihiko Shimokawa, Katsunori Sasahara, Ken Umehara   +2 more
exaly  

Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis

Antimicrobial Agents and Chemotherapy, 2017
Izuru Nakamura, Erina Hanaki
exaly  

Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)

Tuberculosis, 2018
Yongge Liu, Jeffrey Hafkin
exaly